References
ARIMIDEX (anastrozole): Efficacy vs. Tamoxifen

Efficacy—

In initial adjuvant therapy vs tamoxifen...

Efficacy of ARIMIDEX

Latest 100-month ATAC trial results analysis

ARIMIDEX is the only aromatase inhibitor with over 8 years of clinical data—5 years on treatment and more than 3 years of follow-up that demonstrate efficacy and safety in the initial treatment of early breast cancer in postmenopausal women.

The ATAC (ARIMIDEX, Tamoxifen Alone or in Combination) 100-month follow-up data show ARIMIDEX continues to be superior to tamoxifen in improving disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer.11

Download The Lancet article for 100-month ATAC trial analysis


For more information, click on the links below:


Dr. Buzdar on ATAC

Dr. Buzdar discusses the 100-month follow-up data showing ARIMIDEX continues to be superior to tamoxifen in improving disease-free survival:

Important Safety Information

Back to top


ARIMIDEX…helps reduce her risk of recurrence

Disease Free Survival

11. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.

* Disease-free survival is defined as the time between randomization and the earliest occurrence of locoregional recurrence, distant recurrence, contralateral new breast cancer, or death from any cause.

† Hormone receptor positive.

  • Significant (15%) relative improvement in disease-free survival in the HR+ population still evident at 100-month median follow-up11
    • 618 events with ARIMIDEX vs 702 events with tamoxifen
  • Absolute differences in disease-free survival continue to favor ARIMIDEX over tamoxifen in the HR+ population at 100-month median follow-up11
    • 2.5% at 5-year follow-up
    • 4.1% at 9-year follow-up
  • No difference in overall survival at the 100-month median follow-up (intent-to-treat population: hazard ratio=1.00; 95% CI 0.89–1.12)11

Important Safety Information

Back to top



Time to recurrence

1. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.

11. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.

* Time to distant recurrence is defined as the time between randomization and the first report of distant recurrence, censoring deaths without recurrence.

† At 68-month median follow-up Hazard ratio=0.84 (95% CI 0.70-1.00) P=0.06

  • Significant (16%) relative improvement in time to distant recurrence in HR+ population at 100-month median follow-up11
    • 305 events with ARIMIDEX vs 357 events with tamoxifen
  • Absolute differences in time to distant recurrence favor ARIMIDEX over tamoxifen in HR+ population at 100-month median follow-up11
    • 1.3% at 5-year follow-up; P=NS1
    • 2.4% at 9-year follow-up

Important Safety Information

Back to top


Breast cancer events

11. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45-53.

14. Data on file, DA-ARI-22. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware.

* Patients may fall into more than one category.

†Disease-free survival is defined as the time between randomization and the earliest occurrence of locoregional recurrence, distant recurrence, contralateral new breast cancer, or death from any cause.

‡ No statistical analysis performed.

$ 5-year, on-treatment distant recurrence in HR+ population: 226 ARIMIDEX vs 265 tamoxifen, HR=0.84, P=0.06.

 

  • ARIMIDEX improves composite disease-free survival endpoint that includes11:
    • locoregional recurrence
    • contralateral breast cancer
    • distant recurrence
    • death from any cause
  • Absolute differences favor ARIMIDEX over tamoxifen in HR+ population at 100-month median follow-up in11:
    • disease-free survival: 2.5% at 5-year follow-up; 4.1% at 9-year follow-up
    • contralateral breast cancer: 0.8% at 5-year follow-up; 1.7% at 9-year follow-up
    • distant recurrence: 1.3% at 5-year follow-up; 2.4% at 9-year follow-up
  • Death after recurrence in HR+ population at 100-month median follow-up was 245 with ARIMIDEX vs 269 with tamoxifen; P=NS1
  • Please see the full Prescribing Information

Important Safety Information

Back to top


AstraZeneca